| 2015 |
AHNAK2 associates with FGF1 in a heat shock-dependent manner (identified by immunoprecipitation mass spectrometry), and both proteins translocate to the cytoskeletal fraction upon heat stress, co-localizing with F-actin near the plasma membrane. Depletion of AHNAK2 drastically reduces stress-induced FGF1 export but does not affect spontaneous FGF2 export or Notch inhibition-induced FGF1 release, placing AHNAK2 as a specific component of the nonclassical FGF1 secretion pathway. |
Immunoprecipitation mass spectrometry, subcellular fractionation, co-localization imaging, siRNA knockdown with FGF1 export assay |
Journal of cellular biochemistry |
Medium |
25560297
|
| 2010 |
AHNAK2 localizes to the costameric network in mouse skeletal muscle fibers, as demonstrated by co-localization with vinculin; no AHNAK2 expression was detected in the T-tubule system. |
Immunofluorescence with specific AHNAK2 antibodies and co-localization with vinculin in mouse skeletal muscle sections |
Biochemical and biophysical research communications |
Medium |
20833135
|
| 2019 |
AHNAK2 binds directly to periaxin (PRX), the protein encoded by the CMT4F-associated PRX gene; compound heterozygous mutations in AHNAK2 in a CMT patient family result in significantly reduced AHNAK2 mRNA and protein levels, suggesting disruption of the AHNAK2-PRX interaction impairs myelination. |
Linkage analysis, whole exome sequencing, direct binding assay (stated as direct binding), patient fibroblast expression analysis (qRT-PCR and western blot) |
Neurogenetics |
Medium |
31011849
|
| 2020 |
AHNAK2 knockdown in lung adenocarcinoma cells suppresses migration, invasion, and EMT, and inhibits TGF-β1-induced Smad3 phosphorylation. When p-Smad3 is pharmacologically inhibited, AHNAK2 knockdown has no additional effect, placing AHNAK2 upstream of or at the level of Smad3 phosphorylation in the TGF-β/Smad3 pathway. |
siRNA knockdown, wound-healing and transwell assays, western blot for p-Smad3/Smad3 and EMT markers, Smad3 phosphorylation inhibitor epistasis experiment |
OncoTargets and therapy |
Medium |
33363388
|
| 2020 |
AHNAK2 knockdown in lung adenocarcinoma A549 cells decreases phosphorylation of MEK, ERK, and p90RSK, and produces effects similar to the MEK inhibitor U0126, placing AHNAK2 as a positive regulator of the MAPK (MEK/ERK) signaling pathway to promote proliferation, migration, and invasion. |
siRNA knockdown, western blot for p-MEK/p-ERK/p-P90RSK, pharmacological comparison with U0126 inhibitor, CCK-8, wound-healing, and transwell assays |
Technology in cancer research & treatment |
Low |
33000678
|
| 2021 |
AHNAK2 knockdown reduces nuclear factor kappa B (NF-κB) pathway activity in thyroid carcinoma cells, as shown by decreased NF-κB signaling markers, inhibiting migration, invasion, and metastasis. |
siRNA knockdown, western blot for NF-κB pathway markers, migration/invasion assays, in vivo metastasis model |
Life sciences |
Low |
34627772
|
| 2021 |
AHNAK2 knockdown in thyroid carcinoma cells inhibits proliferation, metastasis, and EMT, and reduces β-catenin and cyclin D1 protein levels; AHNAK2 overexpression has the opposite effect. Rescue with LiCl (Wnt activator) or ICG-001 (Wnt inhibitor) counteracts the effects of AHNAK2 knockdown or overexpression, respectively, placing AHNAK2 as a positive regulator of the Wnt/β-catenin pathway. |
siRNA knockdown, overexpression, western blot for β-catenin/cyclin D1, pharmacological rescue with LiCl and ICG-001, proliferation/migration/invasion assays |
Neoplasma |
Low |
34374294
|
| 2021 |
Knockdown of AHNAK2 in ESCC cell lines increases radioresistance, and transcriptome analysis indicates AHNAK2 regulates expression of interleukins, interleukin receptors, and chemokines by inhibiting NF-κB and TNF signaling pathways, suppressing immune response in radioresistant cells. |
shRNA knockdown, clonogenic survival after irradiation, transcriptome sequencing/RNA-seq analysis |
OncoTargets and therapy |
Low |
33633453
|
| 2023 |
AHNAK2 physically interacts with RUVBL1 (identified by co-immunoprecipitation and mass spectrometry); AHNAK2 knockdown causes G1/S phase cell cycle arrest in lung adenocarcinoma cells, and GSEA/RNA-seq implicate AHNAK2 in the mitotic cell cycle, DNA replication, and NF-κB signaling. |
shRNA knockdown, RNA sequencing, mass spectrometry, co-immunoprecipitation (Co-IP), cell cycle analysis by flow cytometry |
Thoracic cancer |
Medium |
37349884
|
| 2024 |
AHNAK2 promotes pancreatic ductal adenocarcinoma progression by preventing c-MET protein degradation (post-transcriptional stabilization), maintaining persistent HGF/c-MET signaling; AHNAK2 and c-MET show significant positive correlation at the protein level but not mRNA level, and AHNAK2 knockdown reduces c-MET protein in response to HGF treatment. |
Lentivirus-mediated knockdown, western blot for c-MET protein levels with/without HGF, subcutaneous CDX model and KPC spontaneous mouse model, IHC, qRT-PCR |
Cancer management and research |
Medium |
38751848
|
| 2024 |
AHNAK2 knockdown in pancreatic cancer cells decreases phosphorylated p65, phosphorylated IκBα, and MMP-9 expression; NF-κB activation reverses the effects of AHNAK2 knockdown, placing AHNAK2 upstream of the NF-κB/MMP-9 axis in pancreatic cancer progression. |
siRNA knockdown, western blot for p-p65/p-IκBα/MMP-9, NF-κB activator rescue experiment, CCK-8, scratch, and transwell assays |
Biochemical genetics |
Low |
38864962
|
| 2024 |
AHNAK2 promotes differentiated thyroid cancer cell proliferation, migration, and invasion; knockdown reduces phospho-PI3K p85 and phospho-AKT levels, placing AHNAK2 as a positive regulator of the PI3K/AKT signaling pathway. |
siRNA knockdown, western blot for p-PI3K and p-AKT, CCK-8, colony formation, migration/invasion assays, flow cytometry |
Current cancer drug targets |
Low |
36089788
|
| 2025 |
AHNAK2 co-localizes with Cortactin in filopodia in pancreatic cancer cell lines that show diffuse cytoplasmic AHNAK2 distribution; this co-localization increases on fibronectin, collagen substrates, and in hypoxia, and correlates with augmented cancer cell invasion. Cell lines with vesicular AHNAK2 staining do not show these changes. |
Immunofluorescence co-localization in cell lines, substrate-dependent culture experiments, hypoxia treatment, invasion assay |
Scientific reports |
Low |
39849106
|
| 2025 |
AHNAK2 knockdown in 5-FU-resistant colorectal cancer cells reduces resistance to 5-FU and suppresses PCNA, CDK4, p-AKT, and p-GSK-3β while increasing cleaved caspase-3 and E-cadherin; AHNAK2 overexpression produces opposite effects both in vitro and in vivo, placing AHNAK2 as an activator of the AKT/GSK-3β survival axis that confers chemotherapy resistance. |
siRNA knockdown, overexpression, western blot for AKT/GSK-3β pathway components, CCK-8, colony formation, flow cytometry, wound healing, transwell, tumor xenograft mouse model |
Clinical and experimental medicine |
Medium |
40382757
|
| 2026 |
AHNAK2 knockdown in gastric cancer cells reduces proliferation, invasion, and migration while increasing apoptosis; RNA sequencing and western blot analysis confirm that AHNAK2 mediates GC progression through the Wnt/β-catenin signaling pathway. |
shRNA knockdown, western blot, immunofluorescence, transcriptome RNA sequencing, IHC |
Discover oncology |
Low |
41655165
|